The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -5.64 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -2.52 — no flag raisedOK
- Earnings quality 83/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Axsome Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Product$633.8M
- Royalty And Milestone Revenue$4.7M
Leadership changes
From Axsome Therapeutics, Inc.'s own filings, the day they're filed.
- Susan Mahony · director · appointmenteff. 2023-10-10
- Involuntary Termination · vice president · departure
- Control Period · departure
Latest filings
- 8-K · Company announcement2026-06-09
- 8-K · Company announcement2026-06-09
- 8-K · Company announcement2026-06-03
- 8-K · Company announcement2026-05-04
- 10-Q · Quarterly report2026-05-04
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Axsome Therapeutics, Inc., every answer cited🔒
- The Intelligence Brief — added when Axsome Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.